IMM-004 small molecule series that inhibits NLRP3, NLPR1, NLRC4 & AIM2

Time: 3:00 pm
day: Day 1 - Track A - Afternoon


  • Multiple inflammasomes (NLRP3, NLRP1, NLRC4, AIM2) drive many rare and prevalent diseases such as neuroinflammatory, cardiometabolic and rheumatic disease. While drugging only one inflammasome (NLRP3) has been the key focus in the inflammasome space, NLPR3 inhibition alone may not be sufficient to control many diseases where other inflammasomes are activated or cross-activated. Thus, multi-inflammasome inhibition strategy could be essential for achieving more effective disease control
  • Discovering IMM-004 series of molecules that control IL-1b and IL-18 formation from NLRP3, NLRP1, NLRC4, and AIM2
  • IMM-004 series are novel small molecules, orally bioavailable and brain penetrating. IMM-004 series molecules are being explored for neuro-inflammatory, cardiometabolic and rheumatic diseases